MaxCyte, Inc. Notice of Results (6595S)
July 15 2022 - 8:01AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6595S
MaxCyte, Inc.
15 July 2022
MaxCyte to Report Second Quarter 2022 Financial Results on
August 10, 2022
GAITHERSBURG, MD, July 15, 2022 - MaxCyte, Inc., (NASDAQ: MXCT;
LSE: MXCT), a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization, today announced that
it will release financial results for the second quarter of 2022
after the U.S. market close on Wednesday, August 10(th) , 2022.
Company management will host a conference call to discuss financial
results at 4:30 p.m. Eastern Time.
Conference Call Details
Investors interested in listening to the conference call are
required to register online. It is recommended to register at least
a day in advance. A live and archived webcast of the event will be
available on the "Events" section of the MaxCyte website at
https://investors.maxcyte.com/.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. Over the past 20
years, we have developed and commercialized our proprietary Flow
Electroporation(R) platform, which facilitates complex engineering
of a wide variety of cells. Our ExPERT(TM) platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM) GTx(TM)
and VLx(TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
+44 (0)203 709 5700
UK IR Adviser maxcyte@consilium-comms.com
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORUVSKRUNUBARR
(END) Dow Jones Newswires
July 15, 2022 08:01 ET (12:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024